Pål-Dag Line, MD, PhD
Oslo University Hoapital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Pål-Dag Line, MD, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:16 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06850753 · En Bloc Resection of the Liver and Pancreas With a "Non-touch" Technique Followed by Liver Transplantation to Improve the Overall Survival in Patients With Non-resectable Hilar Cholangiocarcinoma Beyond the Mayo Clinic Transplant CriteriaOslo University Hospital · recruiting · Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Recurrent, Liver Transplantation
- Ph1/Ph2NCT04806737 · Teriflunomide vs. Placebo During Gluten Challenge in Celiac DiseaseOslo University Hospital · completed · Celiac Disease · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:16 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.